This Patented Medicine Prices Review Board (PMPRB) presentation to the 2021 CADTH Symposium compares the emerging Canadian market for biosimilars with other jurisdictions and assesses the impact of recent and upcoming biosimilar switching initiatives, highlighting the potential for cost savings.
